首页 | 本学科首页   官方微博 | 高级检索  
检索        


Successful treatment of linezolid-induced severe lactic acidosis with continuous venovenous hemodiafiltration: A case report
Institution:1. Department of Pharmacy, Department of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Key Laboratory of Immunology in Chronic Diseases, The first Affiliated Hospital of Bengbu Medical College, Anhui, Bengbu, China;2. Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Jiangsu, Nanjing 210008, PR China;3. Department of Pharmacy, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Medical Center for Clinical Pharmacy, Jiangsu, Nanjing 210008, PR China
Abstract:Linezolid is an oxazolidinone antibiotic. Linezolid-associated lactic acidosis has been reported in 6.8% of linezolid-treated patients. Lactic acidosis is associated with poor clinical outcomes, with high blood lactate levels resulting in organ dysfunction and mortality. This case report describes the development of lactic acidosis in a 64-year-old Chinese woman who had received 33 days of treatment with antituberculosis drugs and 28 days of treatment with oral linezolid for tuberculous meningitis. Severe lactic acidosis was reversed by withdrawing antituberculosis drugs and using continuous venovenous hemodiafiltration (CVVH). When the patient's condition was stable, she was transferred to the infectious disease department, and antituberculosis drugs, with the exception of linezolid, were reintroduced. This did not result in recurrence of lactic acidosis. The causal relationship between lactic acidosis and linezolid was categorized as ‘probable’ on the Adverse Drug Reaction Probability Scale. This case demonstrates that CVVH has potential as an alternative to discontinuation of linezolid alone for rapid reversal of linezolid-associated severe lactic acidosis.
Keywords:Linezolid  Lactic acidosis  CVVH  Case report  CVVH"}  {"#name":"keyword"  "$":{"id":"pc_hvPuS3A2NB"}  "$$":[{"#name":"text"  "_":"continuous venovenous hemodiafiltration  arterial partial pressure of oxygen  arterial partial pressure of carbon dioxide  PT"}  {"#name":"keyword"  "$":{"id":"pc_Uzw0kZHvy4"}  "$$":[{"#name":"text"  "_":"prothrombin time  APTT"}  {"#name":"keyword"  "$":{"id":"pc_BLx8skX0GA"}  "$$":[{"#name":"text"  "_":"activated partial thromboplastin time  TT"}  {"#name":"keyword"  "$":{"id":"pc_WnVoc5UqE7"}  "$$":[{"#name":"text"  "_":"thrombin time  FIB"}  {"#name":"keyword"  "$":{"id":"pc_zcvoh9cie1"}  "$$":[{"#name":"text"  "_":"fibrinogen  ICU"}  {"#name":"keyword"  "$":{"id":"pc_SbPitnTtpF"}  "$$":[{"#name":"text"  "_":"intensive care unit  CRRT"}  {"#name":"keyword"  "$":{"id":"pc_KGbBvaOE9z"}  "$$":[{"#name":"text"  "_":"continuous renal replacement therapy  ADR"}  {"#name":"keyword"  "$":{"id":"pc_3ahi66NOPm"}  "$$":[{"#name":"text"  "_":"Adverse Drug Reaction  ESRD"}  {"#name":"keyword"  "$":{"id":"pc_PvRLJmPHMH"}  "$$":[{"#name":"text"  "_":"end-stage renal disease
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号